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Abstract
Aim: To analyze apolipoprotein gene polymorphisms in the Tunisian population and to check the
relation of these polymorphisms and homocysteine, lipid and apolipoprotein levels to the coronary
artery disease (CAD).
Methods: In healthy blood donors and in patients with CAD complicated by myocardial infarction
(MI) four apolipoprotein gene polymorphisms [APO (a) PNR, APO E, APO CI and APO CII] were
determined and plasma levels of total homocysteine, total cholesterol (TC), triglycerides (TG),
HDL-cholesterol (HLD-C) and apolipoproteins (apo A-I, Apo B, Apo E) were measured.
Results:  Analysis of the four apolipoprotein gene polymorphisms shows a relative genetic
homogeneity between Tunisian population and those on the other side of Mediterranean basin.
Compared to controls, CAD patients have significantly higher main concentrations of TC, TG,
LDL-C, apo B and homocysteine, and significantly lower ones of HDL-C, apo A-I and apo E. The
four apolipoprotein gene polymorphisms have not showed any significant differences between
patients and controls. However, the APO E4 allele appears to be associated to the severity of CAD
and to high levels of atherogenic parameters and low level of apo E, which has very likely an anti-
atherogenic role.
Conclusion: Although APO (a) PNR, APO CI and APO CII genes are analyzed in only few
populations, they show a frequency distribution, which is not at variance with that of APO E gene
and other widely studied genetic markers. In the Tunisian population the APO E 4 appears to be
only indirectly involved in the severity of CAD. In the routine practice, in addition of classic
parameters, it will be useful to measure the concentration of apo E and that of Homocysteine and
if possible to determine the APO E gene polymorphism.
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Introduction
Coronary artery disease (CAD) is a multifactorial disease
caused by genetic and environmental factors. Apolipopro-
tein genes involved in lipoprotein synthesis and metabo-
lism are considered excellent candidates for studying the
susceptibility to CAD and myocardial infarction (MI) [1].
Functional variants of genes encoding lipoproteins are
responsible in part for between-individual variation in the
plasma levels of lipoproteins and, therefore, they are
related with the risk for atherosclerosis [2].
Among apolipoproteins, apolipoprotein (a) is a highly
glycosylated protein component of lipoprotein (a) [3]. It
is a highly polymorphic protein whose size varies depend-
ing on the number of Kringle IV type 2 (KIV) repeats [4].
Several polymorphisms of the APO (a) gene have been
described in the 5'-untranslated region [5]. A pentanucle-
otide repeat (PNR) polymorphism (TTTTA)n located 1.3
kb upstream of the first exon in the APO (a) gene (chro-
mosome 6, 6q26-q27) may explain a part of the between-
individual variability of lipoprotein Lp(a) [6]. However,
inconsistent results have been published concerning asso-
ciation of this polymorphism with CAD and/or MI [7,8].
APO E gene, the most extensively studied polymorphism
among apolipoproteins, has three common alleles desig-
nated E2, E3 and E4 coding for three protein isoforms
(apo E2, apo E3 and apo E4, respectively) [9] that serve as
a ligand for members of the low-density lipoprotein
receptor (LDLR) family. This function is extremely impor-
tant for the catabolism of triglyceride rich particles. It has
been demonstrated that the E4 allele is associated with
increased levels of plasma cholesterol, LDL-C, and
increased risk for CAD [10,11].
Apolipoproteins CI and CII are constituents of very low-
density and high-density lipoproteins. The genes coding
for these apolipoproteins are close to the APO E gene on
the long arm of chromosome 19 (19 q13,2). The apo CI
protein inhibits the bindings of beta very low-density and
intermediary density lipoproteins to lipoproteins' recep-
tors. Apo CII is required as a cofactor in the hydrolysis of
triacylglycerides of chylomicrons and VLDL by lipopro-
tein lipase. Two restriction polymorphisms, the HincII site
in the promoter region of the APO CI gene and the AvaII
site in the intron 3 of the APO CII gene [12,13], have been
described in these proteins. The restriction site of APO CI
has been associated with a significant increase of APO CI
gene transcription [14]. Since these three genes are located
in the same chromosome, the effect of the APO E, CI and
CII gene cluster on serum lipid levels has been studied,
particularly in Chinese Han samples of CAD patients
[15,16]. The results suggest that the linkage disequilib-
rium between APO E and APO CI should be, in part,
responsible for the development of CAD.
In the present study we analyze the polymorphism of the
four apolipoprotein genes [APO (a) PNR, APO E, APO CI
and APO CII] in the Tunisian population and we check
the relation of these polymorphisms and homocysteine,
lipid and apolipoprotein levels to CAD.
Materials and methods
Subjects
We conducted a hospital-based case study in 80 patients
(80% men) with CAD complicated by MI (confirmed by
ECG and coronary angiography) that were diagnosed and
treated at the Department of Cardiology of the University
Hospital Fattouma Bourguiba (Monastir, Tunisia). The
mean age at diagnosis was 57.42 ± 8.37 years. Among these
patients, 56 were smokers; 51 had diabetes; 35 had hyperten-
sion and 22 were hyperlipidemic. As a control group, 100
individuals (76% men with age range close to that of the
patient group), free of any CAD or any related disorders,
were randomly selected from the same large geographical
area to which belonged the patients (the center of Tunisia).
Appropriate informed consent was obtained from patients
and controls in accordance with the Ethical Committee
Guidelines of the participating Hospital and University.
Plasma level measurements
Quantitative analyses of homocysteine, lipids and apoli-
poproteins were performed on only 50 controls and 50
patients within 24 h from collection. Plasma levels of total
cholesterol (TC), triglycerides (TG) and HDL-cholesterol
(HDL-C) were measured by an enzymatic colorimetric
assay (using a clinical system, Beckman instruments).
LDL-cholesterol concentrations were calculated by using
the Friedewald formula [17]. Apolipoprotein (apo A-I,
apo B, and apo E) concentrations were determined using
an immunonephelometric assay on the nephelometer
analyser II (Behring). The plasma concentrations of total
homocysteine were measured by fluorescence polariza-
tion immunoassay on the AXSYM system.
DNA analysis
Leukocyte DNA was extracted from blood samples by phe-
nol-chloroform method and amplified by PCR using oli-
gonucleotide primers and amplification conditions
described previously in [6] for the PNR of APO (a), APO
E, APO CI, and APO CII polymorphisms [18,12,13]. Alle-
les of the APO (a) PNR were identified by 10% polyacry-
lamide gel electrophoresis using DNA molecular weight
markers. In the case of APO E, APO CI and APO CII, the
PCR products were digested with Hha, HincII and AvaII
enzymes, respectively and then separated by 10% polyacr-Lipids in Health and Disease 2008, 7:46 http://www.lipidworld.com/content/7/1/46
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ylamide gel for APO E and APO CII and 2% agarose gel
electrophoresis for APO CI.
Statistical analysis
Allelic and genotypic frequencies were calculated by direct
gene counting method. The chi-square test was used to
test Hardy-Weinberg equilibrium of all gene variants. Dif-
ferences in frequencies between cases and controls were
analyzed by Fisher's exact test. Haplotype calculations for
the APO E-CI-CII gene cluster were done by means of the
Arlequin v 2.0 package [19]. The same package was used
to estimate the comparison between our Tunisian sample
and other Mediterranean populations (exact test of popu-
lation differentiation). Lipid and plasma parameter meas-
ures were compared through the student's t-test. The
analysis of variance (ANOVA) was used to compare the
mean lipid, lipoprotein and apolipoprotein levels associ-
ated with APO E genotypes.
Results
Allele and genotype frequencies of the APO (a) PNR, APO
E, APO CI and APO CII polymorphisms analyzed in con-
trols and patients are presented in Table 1. In all cases,
genotype distributions were in Hardy-Weinberg equilib-
rium. APO E-APO CI-APO CII haplotypes are indicated in
Table 2.
Genetic profile of the Tunisian population
APO E allele frequencies of the present control sample
from a wide area of the center of Tunisia are very close to
those previously described in a Tunisian sample repre-
sentative of the whole country (APO E2 = 4.5, APO E3 =
85.9, APO E4 = 9.5) [20]. The lack of significant differ-
ences between Tunisian samples reveals a high degree of
population homogeneity when large geographic areas are
considered. In addition, our control sample does not
show any significant difference with other South Euro-
pean populations. Data on these populations and others
are presented in a previous paper conducted by our
research team [20].
Allele frequencies of APO (a), APO CI, and APO CII poly-
morphisms in the control Tunisian sample are compared
with those found in other populations (Table 3). Con-
cerning APO (a) PNR, the allele of 8 repeats is the most
common (0.635) in Tunisians agreeing with that
Table 1: Allele and genotype frequencies of APO (a) (PNR), APO E, APO CI and APO CII in control and CAD groups.
Allele Allele frequencies Genotype Genotype Frequencies
Control (N = 100) CAD (N = 80) Control (N = 100) CAD (N = 80)
APO (a)
*7 0.145 0.168 7/7 0.020 0.020
*8 0.645 0.650 7/8 0.210 0.240
*9 0.100 0.037 8/8 0.430 0.400
*10 0.045 0.087 8/9 0.110 0.040
*11 0.065 0.056 8/10 0.040 0.100
8/11 0.070 0.120
9/10 0.020 0.020
Others 0.100 0.060
P 0.276 0.182
APO E
*E2 0.045 0.037 E2/E2 - -
*E3 0.870 0.876 E2/E3 0.080 0.080
*E4 0.085 0.087 E2/E4 0.010 -
E3/E3 0.780 0.760
E3/E4 0.130 0.160
E4/E4 - -
P 0.917 0.835
APO CI
*H1 0.915 0.893 H1/H1 0.830 0.820
*H2 0.085 0.107 H1/H2 0.170 0.180
P1 1
APO CII
*A1 0.555 0.512 A1/A1 0.310 0.320
*A2 0.445 0.488 A1/A2 0.490 0.400
A2/A2 0.200 0.280
P 0.618 0.635
Alleles (*H1, *A1) and (*H2, *A2) indicate absence and presence, respectively, of the enzyme restriction site.
P: Probability values for the comparison of allele and genotype frequencies between controls and CAD.Lipids in Health and Disease 2008, 7:46 http://www.lipidworld.com/content/7/1/46
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observed in other South European populations [21-24].
However, our sample exhibits some particular features
such as the lowest and highest frequencies for the alleles
of 10 and 7 repeats, respectively. As a result of this partic-
ular PNR allele distribution, pairwise population compar-
isons reveal remarkable significant differences (p < 0.01)
between our Tunisian sample and the 6 South European
groups recorded in Table 3. Regarding the APO CI poly-
morphism, H1 is the most common allele with a fre-
quency (0.915) similar to that found in several Spanish
populations [21]. For the APO CII polymorphism, the fre-
quencies of both alleles (0.555 for A1 and 0.445 for A2)
are close to the pattern of variation observed in some
Spanish groups [21]. No significant differences have been
detected between Tunisians and Spaniards for these two
gene polymorphisms.
The pattern of allele variation in North Africa (Table 3) is
represented only by a Moroccan Berber group sample [25]
of ethnically Berber communities dispersed and more and
less isolated in the Middle Atlas mountainous region. No
significant differences have been observed between our
sample and this Berber group for the APO CI polymor-
phism. However, for both the APO (a) PNR and the APO
CII polymorphisms we have found significant differences
(p = 0.010 and p = 0.031, respectively). In fact, the rela-
tively distinctive genetic features of this Berber group
beside the general genetic profile of the North African
populations as that of Tunisia suggests the influence of
isolation events in its genetic background.
Comparative analyses between control and CAD groups
Lipid, lipoprotein and apolipoprotein mean concentra-
tions are indicated in Table 4. Compared to controls, CAD
patients have significantly higher values of TC, TG (triglyc-
erides), LDL-C, apo B and homocysteine, but significantly
lower values of HDL-C, apo A-I and apo E. The increased
Table 2: APO E - CI - CII haplotype distribution in CAD and 
control subjects.
Haplotype Control CAD
E2 - H1 - A1 0.0107 -
E2 - H1 - A2 --
E2 - H2 - A1 0.0342 0.0191
E2 - H2 - A2 - 0.0183
E3 - H1 - A1 0.4155 0.4107
E3 - H1 - A2 0.4216 0.4446
E3 - H2 - A1 0.0167 0.0196
E3 - H2 - A2 0.0160 -
E4 - H1 - A1 0.0596 0.03836
E4 - H1 - A2 0.0072 -
E4 - H2 - A1 0.0180 0.0247
E4 - H2 - A2 - 0.0244
P 0.922
P: Probability values for the comparison of haplotype frequencies 
between controls and CAD.
Table 3: Distribution of APO (a), APO CI, and APO CII in Tunisian population and others Mediterranean populations.
Population N Allele frequencies % References
APO (a) *5 *6 *7 *8 *9 *10 *11
Tunisia 100 0.0 0.0 14.5 64.5 10 4.5 6.5 Present study
Catalonia 88 0.0 0.6 0.6 68.2 14.2 15.9 0.6 21
Center Spain 120 0.0 0.4 0.4 76.2 12.9 8.7 1.3 21
Basque 112 0.0 0.4 0.4 69.2 18.3 11.2 0.4 21
France 199 0.2 0.2 1.0 75.9 10.5 10.7 1.5 22
Italy 218 0.0 0.0 1.1 63.0 17.0 15.0 3.9 23
Corsica  47 0.0 0.0 0.0 77.7 6.4 14.9 1.1  24 
Morocco (Berbers) 138 0.4 0.0 2.9 63.8 10.9 11.6 10.5 25
APO CI *H1 *H2
Tunisia 100 91.5 8.5 Present study
Catalonia 88 84.7 15.3 21
Center Spain 120 85.4 14.6 21
Basque 111 87.4 12.6 21
Morocco (Berbers) 120 85.0 15.0 25
APOCII *A1 *A2
Tunisia 100 55.5 44.5 Present study
Catalonia 88 55.7 44.3 21
Center Spain 114 48.7 51.3 21
Basque 112 51.3 48.7 21
Morocco (Berbers) 117 70.1 29.9 25
N: sample size.
Alleles (*H1, *A1) and (*H2, *A2) indicate absence and presence, respectively, of the enzyme restriction site.Lipids in Health and Disease 2008, 7:46 http://www.lipidworld.com/content/7/1/46
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apo B levels together with the decreased apo A-I levels
contribute to increase the apo B/apo A-I ratio, a quotient
commonly accepted as a risk factor for CAD.
No significant differences have been detected between
patients and controls neither for apolipoprotein gene fre-
quencies (Table 1) nor for the haplotype distribution
(Table 2) of the APO E-APO CI- APO CII gene cluster.
Concerning this cluster, the linkage disequilibrium analy-
sis showed a strong association (p < 0.0001) between
APO E and APO CI in both groups and between APO E
and APO CII only in controls (p = 0.008).
In spite of the lack of significant differences between
patients and controls, several features are worth noting
particularly at the level of APO E polymorphism. In the
case of APO (a) PNR polymorphism, whereas the 8
repeats allele is found with similar frequencies in both
groups, the frequency of the 9 repeats allele is higher in
the control group. On the other hand, the 7 repeats allele
frequency is higher in the CAD group.
As for APO E polymorphism, when the CAD sample is
divided in two groups: hyperlipidemic (TC> 5.70 mmol/
l) and non-hyperlipidemic subjects, the APO E4 allele is
significantly (p < 0.05) higher in the hyperlipidemic
patients (20.45% versus 3.51%, respectively). The same is
true for the controls, although they all have normal TC
concentrations (between 3 and 5 mmol/l) when controls
are divided in two groups, a group with TC< 4 mmol/l and
a second with TC> 4 mmol/l, the APO E4 allele is signifi-
cantly (p < 0.05) higher in the second group (28.85% ver-
sus 8.33%, respectively).
Table 4: Lipid and apolipoprotein mean concentrations (± SD) in controls and CAD patients.
Control (N = 50) CAD (N = 50) P
TC (mmol/L) 4.01 ± 0.46 4.62 ± 0.9 <0.001
TG (mmol/L) 0.78 ± 1.78 1.76 ± 0.77 <0.001
HDL-C (mmol/L) 1.07 ± 0.12 0.92 ± 0.26 <0.001
LDL-C (mmol/L) 2.57 ± 0.44 2.95 ± 0.86 <0.01
Apo AI (g/L) 1.33 ± 0.17 1.04 ± 0.13 <0.001
Apo B (g/L) 0.76 ± 0.18 1.00 ± 0.35 <0.001
Apo E (mg/L) 50.24 ± 7.63 43.24 ± 11.33 <0.001
Apo B/ApoAI 0.59 ± 0.16 0.96 ± 0.31 <0.001
Homocysteine (μmol/L) 12.93 ± 1.12 16.6 ± 4.58 <0.001
P: Student t-test probability for comparisons among Control and CAD groups.
Table 5: Effect of APO E genotypes on plasma lipid and apolipoprotein profile in control and CAD groups.
Genotype E2/E3 (6 controls, 4 CAD) E3/E3 (25 controls, 38 CAD) E3/E4 (16 controls, 8 CAD) P
*TC
Controls 3.48 ± 0.35 4.04 ± 0.49 4.20 ± 0.35 0.005
CAD 4.04 ± 1.07 4.58 ± 0.62 5.40 ± 0.67 0.007
*TG
Controls 0.88 ± 0.10 0.73 ± 0.16 0.83 ± 0.19 0.767
CAD 1.40 ± 0.77 1.74 ± 0.70 2.11 ± 0.93 0.314
*HDL-C
Controls 0.95 ± 0.09 1.12 ± 0.09 1.07 ± 0.13 0.074
CAD 0.86 ± 0.39 0.92 ± 0.25 0.93 ± 0.28 0.928
*LDL-C
Controls 2.12 ± 0.38 2.56 ± 0.46 2.75 ± 0.38 0.014
CAD 2.55 ± 0.29 2.82 ± 0.70 3.77 ± 0.60 0.017
*Apo A-I
Controls 1.33 ± 0.29 1.36 ± 0.16 1.27 ± 0.13 0.797
CAD 1.10 ± 0.12 1.03 ± 0.14 1.07 ± 0.13 0.939
*Apo B
Controls 0.61 ± 0.06 0.73 ± 0.18 0.85 ± 0.16 0.016
CAD 0.67 ± 0.16 0.98 ± 0.36 1.23 ± 0.29 0.038
*Apo E
Controls 57.00 ± 6.07 53.77 ± 6.59 44.62 ± 5.40 0.001
CAD 56.50 ± 20.74 42.65 ± 9.90 39.37 ± 8.76 0.043
Data is expressed as mean ± SD; P: Probability values obtained by ANOVA for the comparison between E2/E3 and E3/E4 genotype groups.Lipids in Health and Disease 2008, 7:46 http://www.lipidworld.com/content/7/1/46
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Given this relation between the APO E polymorphism
and the TC concentration, we have analyzed the influence
of APO E genotypes on the distribution of all studied
lipid, lipoprotein and apolipoprotein concentrations
(Table 5). In the patients and control groups, the subjects
have been regrouped according to their E2/E3, E3/E3 or
E3/E4 genotypes. The E2/E4 genotype is not considered,
because it has been found in only three subjects of the
control group. Both in patients and controls, we have
compared individuals having E2 (E2/E3) with those hav-
ing E4 (E4/E3). Those having E2 show significant low lev-
els of TC, LDL-C and apo B, whereas those having E4 show
significant high values of these parameters. Apo E concen-
trations are also affected by APO E genotypes in the two
groups. E2 carriers show high significant concentration
while E3/E3 genotypes have an intermediate value and E4
carriers show a significantly low value (Table 5). Mean
concentrations of other lipid parameters such as HDL-C,
TG and apo A-I are not significantly different among the
three APO E genotypes.
The severity of CAD in our sample has been estimated by
the number (1, 2, or 3) of affected coronary vessels. Allele
distributions of apolipoprotein gene polymorphisms in
patients with 1, 2 and 3 affected vessels are shown in Table
6. Allele distribution comparisons between patients with
1 and 3 affected vessels have shown a significant differ-
ence (p = 0.005) only for the APO E allele comparison.
This fact suggests an association between APO E polymor-
phisms and CAD severity. In fact, the frequency of APO E4
increases whereas the frequencies of both APO E2 and
APO E3 decrease with the increased number of affected
vessels.
Discussion
In this study we have analyzed for the first time the poly-
morphisms of APO (a) PNR, APO E, APO CI and APO CII
genes together with several lipid and apolipoprotein lev-
els in Tunisian CAD patients and in controls. This consti-
tutes an approach to the genetic characterization of the
lipid profiles of Tunisian cardiovascular patients and sup-
plies anthropological data on the Tunisian population.
Although APO (a) PNR, APO CI and APO CII gene poly-
morphisms have been analyzed in only few populations
from South Europe (Table 2), they show frequency distri-
bution between Mediterranean populations similar to
that found according to APO E gene and other widely ana-
lyzed genetic markers [for review see [20,26-28]]. In fact,
we have found modest significant differences among our
Tunisian sample and those of South Europe only for the
APO (a) PNR distribution. Thus, populations of the two
Mediterranean shores share a relative genetic homogene-
ity that probably reflects a common origin and/or remark-
able levels of gene flow.
Comparative analyses between control and CAD groups
from Tunisia have shown important observations, partic-
ularly in comparison with those found in other popula-
tions. Concerning the analyses of plasma lipid mean
Table 6: Apolipoprotein allele frequencies and CAD severity.
Apolipoprotein alleles CAD severity (N = 80) P
1 vessel (n = 35) 2 vessels (n = 31) 3 vessels (n = 14)
APO (a) alleles n (%) n (%) n (%) 0.121
7 13 18.57 11 17.74 3 10.71
8 49 70.00 39 62.9 16 57.14
9 2 2.86 4 6.45 0 0.00
10 2 2.86 6 9.68 6 21.42
11 4 5.71 2 3.23 3 10.71
APOE alleles n (%) n (%) n (%) 0.005
E2 4 5.71 3 4.84 0 0.00
E3 64 91.42 55 88.7 20 71.43
E4 2 2.85 4 6.45 8 28.57
APOCI alleles n (%) n (%) n (%) 0.285
H1 64 91.42 56 90.32 23 82.14
H2 6 8.57 6 9.68 5 17.85
APOCII alleles n (%) n (%) n (%) 1
A1 33 47.14 36 58.07 13 46.42
A2 37 52.85 26 41.93 15 53.57
P: probability values for the comparison of allele distribution between patients with 1 and 3 affected vessels.Lipids in Health and Disease 2008, 7:46 http://www.lipidworld.com/content/7/1/46
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concentrations, the significant high values of TC, LDL-C,
apo B and TG, and the significant low values of HDL-C,
apo A-I, and apo E shown by Tunisian patients with CAD
have been also observed in other populations [29,30]. The
homocysteine concentration, that shows mean values
around 28.4% higher in CAD Tunisian patients than in
controls, presents a linear relationship with the severity of
CAD (14.67 μmol/L, 17.46 μmol/L, and 18.7 μmol/L for
1, 2 and 3 affected vessels respectively, p < 0.05). This rela-
tionship suggests that high homocysteine levels are asso-
ciated with CAD and with its severity. Similar
observations have been found in Iranian and Greek pop-
ulations [31,32] but not demonstrated in a sample of
American population [33]. It will be interesting to check
this association in other populations and to add the quan-
tification of homocysteine to the classic parameters ana-
lyzed in the routine practice.
In the case of the APO CI and APO CII polymorphisms,
no association was noted with CAD. In fact, only few stud-
ies have analyzed the association of these polymorphisms
with the disease. In a study on the Chinese population
[16] the authors found that only APO CI polymorphism
was associated with CAD.
Regarding the APO (a) PNR polymorphism, we ascer-
tained a global negative association between the number
of TTTTA repeats and CAD. This agrees with conclusions
relating to Russian, French and Irish populations [8,34].
However, general associations between "short" TTTTA
repeats (less than 10 repeats) and MI or CAD have been
reported in other populations [7,23,35,36]. In addition,
in this study we have noted that when the allele distribu-
tion is considered in relation to the severity of the disease
(Table 6) a trend, although not significant, appears
towards an increase of larger (≥ 10 repeats) alleles in the
subgroup with major severity. While, in a previous study
on the Japanese population, the authors showed that the
homozygous genotype for the "short" 8 repeats allele was
related to the number of diseased vessels [7].
The differences in results on CAD risk noted between pop-
ulations probably reflect the complexity of the involve-
ment of many genetic and environmental factors in CAD
appearance. In fact, these risk factors are probably candi-
date factors and the appearance of the CAD does not need
the presence of all of them. Namely, in a given population
the presence of only some (effecter factor group) of these
candidate factors, are enough for favoring the CAD
appearance without or with slight secondary influence of
the other factors. The effecter factor group is very likely the
result of a complex gene-environmental interaction,
which can vary from a population to another. Our obser-
vations relating to APO E polymorphism may illustrate
this proposal.
In some populations (Italian, Turk and Iranian) a signifi-
cantly higher frequency of APO E4 allele was observed in
CAD patients compared with healthy subjects
[10,11,30,37]. Thus, APO E4 allele can be considered
among candidate risk factors for CAD. However, in our
Tunisian population as in Kuwaiti, Polish and Finnish
populations [38-40] no significantly higher frequency of
APO E4 allele has been found in CAD patients. Namely,
in these populations APO E4 allele is not among effecter
factor group and it is without or with slight secondary
influence on the appearance of CAD. In fact, this slight
secondary influence is shown both in the Tunisian and
the Finnish [40] populations by an association between
the APO E4 allele and the CAD severity.
The study of the impact of APO E genotype variations on
serum lipid parameters shows that CAD patients and
healthy subjects with APO E4 allele have higher levels of
atherogenic parameters (TC, LDL-C and apo B), whereas
subjects with APO E2 allele have low levels of these
parameters. Such APO E allele effects have been also
noted in some other populations [11,30]. The impact of
APO E allelic variation in the TC, LDL-C and apo B levels
is mainly due to up and down regulation of LDL receptors
by the E2 and E4 alleles respectively [41].
The effect of APO E4 on CAD severity could be the conse-
quence of its association to significant high levels of ather-
ogenic parameters and its association to low levels of apo
E. In fact, the significant low mean concentration of apo E
in CAD patients, observed also in the Italian population
[10,30] suggests that apo E plays an anti-atherogenic role.
The effect of APO E genotypes on HDL-C concentration
has not demonstrated the same consistency across popu-
lations. In the present study, no association has been
found between APO E polymorphism and HDL-C con-
centrations in both patient and control groups. The rela-
tion of APO E polymorphism and HDL-C has been
reported in some populations [11,37,42] but not in others
[30,43]. These differences between populations can be
explained by gene-environmental interaction. Indeed,
HDL-C levels are affected by exercise and alcohol con-
sumption [44,45].
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